Alan Ridgeway
Recent Quotes
"ONCY is well positioned as the market leader in virus-medicated cancer therapy."
—
Alan Ridgeway, Paradigm Capital
(10/1/13)
more >
"The second half of 2013 should be transformational for ONCY."
—
Alan Ridgeway, Paradigm Capital
(7/12/13)
more >
"We maintain our Buy rating on ONCY."
—
Alan Ridgeway, Paradigm Capital
(2/11/13)
more >
"ONC announced its first positive randomized data for Reolysin."
—
Alan Ridgeway, Paradigm Capital
(12/14/12)
more >
"ONC's Reolysin has the opportunity to be a transformational cancer therapeutic."
—
Alan Ridgeway, Paradigm Capital
(11/12/12)
more >
"ONC's prudent decision could lead to Reolysin use in a larger market."
—
Alan Ridgeway, Paradigm Capital
(9/13/12)
more >
"H2/12 should be transformational for ONC."
—
Alan Ridgeway, Paradigm Capital
(7/9/12)
more >
"ONC has a potential multibillion-dollar market opportunity with Reolysin."
—
Alan Ridgeway, Paradigm Capital
(6/20/12)
more >
